Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

93 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Pancreatic Cancer NCT01473303 Registration - CALGB-81003 OPEN Registration Worksheet (SPARE Phase Ib) - 3340712v1.0 - CALGB-81003 OPEN Registration Worksheet (SPARE Phase Ib)

- 09/01/2015 - 1 Formulaire, 8 Groupes Item, 22 Eléments de données, 1 Langue
Groupes Item: Protocol Administration, Pre-Treatment Characteristics, Certification Of Eligibility, Protocol Design, Prior Cancer Therapies, Study 71102: Patient-reported Outcomes Companion Study, Study 151109: Blood and Tumor Biomarker Companion Study and Study 61103: PG and PK Companion Study, Companion Studies
CALGB-81003 OPEN Registration Worksheet (SPARE Phase Ib) Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B5545048-A6BC-B965-E040-BB89AD437802

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1) - 2866961v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1)

- 09/01/2015 - 1 Formulaire, 1 Groupe Item, 21 Eléments de données, 1 Langue
Groupe Item: MODULE 1
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Radiotherapy Form (T1) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=69073BF6-D406-B01F-E040-BB89AD4319AC

dbGaP phs001003 Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets - pht010322.v2.p1

- 06/11/2023 - 6 Formulaires, 1 Groupe Item, 2 Eléments de données, 1 Langue
Groupe Item: pht010322
Principal Investigator: Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Colonic Neoplasms,Ovarian Neoplasms,Stomach Neoplasms,Cholangiocarcinoma,Pancreatic Neoplasms,Rectal Neoplasms,Esophageal Neoplasms,Colorectal Neoplasms,Endometrial Neoplasms,Paraneoplastic Syndromes, Ocular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001003 Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In this study, we performed whole exome and RNA-Seq analysis metastases to determine the nature and frequency of somatic mutations.

pht010323.v2.p1

1 Groupe Item 2 Eléments de données

pht010324.v2.p1

1 Groupe Item 4 Eléments de données

pht010325.v1.p1

1 Groupe Item 2 Eléments de données

pht010326.v2.p1

1 Groupe Item 5 Eléments de données

Eligibility

1 Groupe Item 9 Eléments de données

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT) - 2891794v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT)

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Footer Module
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Additional Systemic Treatment Summary Form (AT) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AFC2AE9-5C38-1FC0-E040-BB89AD4334D1

Pancreatic Cancer NCT01013649 Treatment - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) - 2867004v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF)

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Footer Module
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Systemic Treatment Summary Form (SF) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=690785CE-F693-0044-E040-BB89AD432A23

Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA) - 2865273v1.0 - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA)

- 09/01/2015 - 1 Formulaire, 4 Groupes Item, 36 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, QOL Cover Sheet, FACIT-Fatigue Subscale
RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment FACIT - Fatigue Cover Sheet (FA) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68B33AD0-8068-FF39-E040-BB89AD430ECB

Pancreatic Cancer NCT01013649 On-Study - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3) - 2865008v1.0 - RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3)

- 09/01/2015 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Header Module, Header
RTOG 0848: Phase III Pancreas-Resected + Adjuvant Treatment Post ARM 1 or 2 Tumor Status Form (F3) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68A15631-F4DE-4C22-E040-BB89AD431280

Pancreatic Cancer NCT01013649 Quality of Life - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) - 2865750v1.0 - RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR)

- 09/01/2015 - 1 Formulaire, 4 Groupes Item, 30 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, QOL Cover Sheet, PROMIS Fatigue Short Form 1
RTOG 0848 Phase III Pancreas-Resected + Adjuvant Treatment PROMIS Fatigue Short Form-1 Cover Sheet (PR) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=68B36F4B-6CF7-CD4B-E040-BB89AD4309CF

Prostate Cancer NCT01546987 Quality of Life - RTOG 1115 HP: Phase III RT + Standard ADT vs RT + Enhanced ADT + TAK-700 PROMIS Form - 3289372v1.0 - RTOG 1115 HP: Phase III RT + Standard ADT vs RT + Enhanced ADT + TAK-700 PROMIS Form

- 09/01/2015 - 1 Formulaire, 3 Groupes Item, 30 Eléments de données, 1 Langue
Groupes Item: Header Module, QOL Cover Sheet, Fatigue - Short Form 1
RTOG 1115 HP: Phase III RT + Standard ADT vs RT + Enhanced ADT + TAK-700 PROMIS Form Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AE8F0868-80F7-FEC9-E040-BB89AD4357E7

SOUTHWEST ONCOLOGY GROUP S0205 BASELINE PHYSICAL EXAMINATION FORM NCT00075686

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Header, Physical examination
SOUTHWEST ONCOLOGY GROUP S0205 BASELINE PHYSICAL EXAMINATION FORM NCT00075686 S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F2FD44E4-4DFA-66A0-E034-0003BA3F9857

S0205 Registration Form NCT00075686

- 20/09/2021 - 1 Formulaire, 4 Groupes Item, 29 Eléments de données, 1 Langue
Groupes Item: SWOG clinical trial administrative data, Patient demographics, Comments, CCRR MODULE
S0205 Registration Form NCT00075686 S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A11C9703-C8D4-1BF2-E034-080020C9C0E0

On-Study Form NCT00058149

- 20/09/2021 - 1 Formulaire, 8 Groupes Item, 74 Eléments de données, 1 Langue
Groupes Item: ECOG clinical trial administrative data, Patient vital status, Disease Description, Site(s) of Involvement, Baseline Hematology/Chemistry, Prior Therapy, CCRR MODULE, Footer module
On-Study Form NCT00058149 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D6B91-79C6-4288-E034-0003BA0B1A09

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial